LiveBoost: A GB-based prediction system for liver fibrosis in chronic hepatitis B patients in China - A multi-center retrospective study

Guoxiang Xie; Huanming Xiao; Quan Liu; Tianlu Chen; Fengyan Chen; Kejun Zhou; Xiaoning Wang; Ping Liu; Zhifeng Jia; Lei Chen; Xin Deng; Fankun Meng; Zhenhua Zhang; Xiaoling Chi; Wei Jia

doi:10.1016/j.heliyon.2024.e24161

LiveBoost: A GB-based prediction system for liver fibrosis in chronic hepatitis B patients in China - A multi-center retrospective study

Guoxiang Xie^*
, Huanming Xiao
, Quan Liu
, Tianlu Chen
, Fengyan Chen
, Kejun Zhou
, Xiaoning Wang
, Ping Liu
, Zhifeng Jia
, Lei Chen
, Xin Deng
, Fankun Meng
, Zhenhua Zhang
, Xiaoling Chi^*
, Wei Jia^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › peer-review

1 Citation (Scopus)

Abstract

Background: The aim of this study was to evaluate the accuracy of LiveBoost™, a gradient boosting (GB)-based prediction system based on standard biochemical values (AST, ALT, platelet count) and age, in Chinese patients with chronic hepatitis B (CHB) and compare its performance with FIB-4 (fibrosis-4 score) and APRI (the aspartate transaminase to platelet ratio index).

Methods: This retrospective trial enrolled 454 participants, including 279 CHB patients who underwent liver biopsy and 175 normal controls from 3 centers in China. All participants underwent laboratory blood testing. LiveBoost was constructed using GB and FIB-4 and APRI were calculated from laboratory data.

Results: LiveBoost outperformed APRI and FIB-4 in predicting hepatic fibrosis and cirrhosis. The GB model had an AUROC of 0.977 for CHB diagnosis, 0.804 for early and advanced fibrosis, and 0.836 for non-cirrhosis and cirrhosis, compared to AUROC of 0.554, 0.673 and 0.720 for FIB-4, AUROC of 0.977, 0.652 and 0.654 for APRI.

Conclusions: LiveBoost is a more reliable and cost-effective method than APRI and FIB-4 for assessing liver fibrosis in Chinese patients with CHB.

Original language	English
Article number	e24161
Number of pages	9
Journal	Heliyon
Volume	10
Issue number	2
DOIs	https://doi.org/10.1016/j.heliyon.2024.e24161
Publication status	Published - 30 Jan 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

User-Defined Keywords

APRI
Chronic hepatitis B
FIB-4
Hepatic fibrosis
LiveBoost

Access to Document

10.1016/j.heliyon.2024.e24161

Cite this

@article{ab9382f41d624096809606d3e2c003a2,

title = "LiveBoost: A GB-based prediction system for liver fibrosis in chronic hepatitis B patients in China - A multi-center retrospective study",

abstract = "Background: The aim of this study was to evaluate the accuracy of LiveBoost{\texttrademark}, a gradient boosting (GB)-based prediction system based on standard biochemical values (AST, ALT, platelet count) and age, in Chinese patients with chronic hepatitis B (CHB) and compare its performance with FIB-4 (fibrosis-4 score) and APRI (the aspartate transaminase to platelet ratio index).Methods: This retrospective trial enrolled 454 participants, including 279 CHB patients who underwent liver biopsy and 175 normal controls from 3 centers in China. All participants underwent laboratory blood testing. LiveBoost was constructed using GB and FIB-4 and APRI were calculated from laboratory data.Results: LiveBoost outperformed APRI and FIB-4 in predicting hepatic fibrosis and cirrhosis. The GB model had an AUROC of 0.977 for CHB diagnosis, 0.804 for early and advanced fibrosis, and 0.836 for non-cirrhosis and cirrhosis, compared to AUROC of 0.554, 0.673 and 0.720 for FIB-4, AUROC of 0.977, 0.652 and 0.654 for APRI.Conclusions: LiveBoost is a more reliable and cost-effective method than APRI and FIB-4 for assessing liver fibrosis in Chinese patients with CHB.",

keywords = "APRI, Chronic hepatitis B, FIB-4, Hepatic fibrosis, LiveBoost",

author = "Guoxiang Xie and Huanming Xiao and Quan Liu and Tianlu Chen and Fengyan Chen and Kejun Zhou and Xiaoning Wang and Ping Liu and Zhifeng Jia and Lei Chen and Xin Deng and Fankun Meng and Zhenhua Zhang and Xiaoling Chi and Wei Jia",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. Published by Elsevier Ltd.",

year = "2024",

month = jan,

day = "30",

doi = "10.1016/j.heliyon.2024.e24161",

language = "English",

volume = "10",

journal = "Heliyon",

issn = "2405-8440",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - LiveBoost

T2 - A GB-based prediction system for liver fibrosis in chronic hepatitis B patients in China - A multi-center retrospective study

AU - Xie, Guoxiang

AU - Xiao, Huanming

AU - Liu, Quan

AU - Chen, Tianlu

AU - Chen, Fengyan

AU - Zhou, Kejun

AU - Wang, Xiaoning

AU - Liu, Ping

AU - Jia, Zhifeng

AU - Chen, Lei

AU - Deng, Xin

AU - Meng, Fankun

AU - Zhang, Zhenhua

AU - Chi, Xiaoling

AU - Jia, Wei

PY - 2024/1/30

Y1 - 2024/1/30

N2 - Background: The aim of this study was to evaluate the accuracy of LiveBoost™, a gradient boosting (GB)-based prediction system based on standard biochemical values (AST, ALT, platelet count) and age, in Chinese patients with chronic hepatitis B (CHB) and compare its performance with FIB-4 (fibrosis-4 score) and APRI (the aspartate transaminase to platelet ratio index).Methods: This retrospective trial enrolled 454 participants, including 279 CHB patients who underwent liver biopsy and 175 normal controls from 3 centers in China. All participants underwent laboratory blood testing. LiveBoost was constructed using GB and FIB-4 and APRI were calculated from laboratory data.Results: LiveBoost outperformed APRI and FIB-4 in predicting hepatic fibrosis and cirrhosis. The GB model had an AUROC of 0.977 for CHB diagnosis, 0.804 for early and advanced fibrosis, and 0.836 for non-cirrhosis and cirrhosis, compared to AUROC of 0.554, 0.673 and 0.720 for FIB-4, AUROC of 0.977, 0.652 and 0.654 for APRI.Conclusions: LiveBoost is a more reliable and cost-effective method than APRI and FIB-4 for assessing liver fibrosis in Chinese patients with CHB.

AB - Background: The aim of this study was to evaluate the accuracy of LiveBoost™, a gradient boosting (GB)-based prediction system based on standard biochemical values (AST, ALT, platelet count) and age, in Chinese patients with chronic hepatitis B (CHB) and compare its performance with FIB-4 (fibrosis-4 score) and APRI (the aspartate transaminase to platelet ratio index).Methods: This retrospective trial enrolled 454 participants, including 279 CHB patients who underwent liver biopsy and 175 normal controls from 3 centers in China. All participants underwent laboratory blood testing. LiveBoost was constructed using GB and FIB-4 and APRI were calculated from laboratory data.Results: LiveBoost outperformed APRI and FIB-4 in predicting hepatic fibrosis and cirrhosis. The GB model had an AUROC of 0.977 for CHB diagnosis, 0.804 for early and advanced fibrosis, and 0.836 for non-cirrhosis and cirrhosis, compared to AUROC of 0.554, 0.673 and 0.720 for FIB-4, AUROC of 0.977, 0.652 and 0.654 for APRI.Conclusions: LiveBoost is a more reliable and cost-effective method than APRI and FIB-4 for assessing liver fibrosis in Chinese patients with CHB.

KW - APRI

KW - Chronic hepatitis B

KW - FIB-4

KW - Hepatic fibrosis

KW - LiveBoost

UR - https://www.scopus.com/pages/publications/85182010709

U2 - 10.1016/j.heliyon.2024.e24161

DO - 10.1016/j.heliyon.2024.e24161

M3 - Journal article

AN - SCOPUS:85182010709

SN - 2405-8440

VL - 10

JO - Heliyon

JF - Heliyon

IS - 2

M1 - e24161

ER -

LiveBoost: A GB-based prediction system for liver fibrosis in chronic hepatitis B patients in China - A multi-center retrospective study

Abstract

UN SDGs

User-Defined Keywords

Access to Document

Other files and links

Fingerprint

Cite this